Thanks! We’re so glad you’re here!
We’ll keep you posted on the future of pet cancer care with our email newsletter.
Until the next delivery, check out some of our latest articles below.
Check Out Our Recent Posts
Promising New Data Demonstrates Chemo-Immunotherapy Treatment Approach with ECI® Significantly Improves Outcomes in Dogs with Bone Cancer
LENEXA, Kan. – September 23, 2025 – ELIAS Animal Health, a leader in advancing novel therapies for veterinary cancer care, has published new data from [...]
ELIAS Animal Health to Present New Research at Upcoming Human and Veterinary Oncology Conferences
LENEXA, Kan., September 4, 2025 -- ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising [...]
Immunotherapy Combined with a Single Dose of Chemotherapy Shows Improved Outcomes in Dogs with Bone Cancer
Recently, ELIAS Animal Health announced new data on a chemo-immunotherapy approach using the ELIAS Cancer Immunotherapy (ECI®) to treat canine osteosarcoma that demonstrated improved outcomes. [...]
More Than a Cancer Vaccine
The ELIAS Cancer Immunotherapy (ECI®) if the first and only USDA-approved product for the treatment of canine osteosarcoma. ECI® is unique because of its dual approach to treatment: it brings together the power of a personalized cancer vaccination and activated “killer” T cell therapy to trigger the patient’s own immune system to attack cancer cells. Our immunotherapy enables veterinary care providers like you to:
Extend hope for families of pets with cancer
Make a measurable difference for your patients
Help improve outcomes with minimal adverse side effects